Monopar Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	11	5	30	40	70	173
Market Cap Growth	-	-83.40%	-24.61%	-42.33%	-59.48%	-
Enterprise Value	5	-2	17	20	53	160
PE Ratio	-0.60	-0.60	-2.90	-4.44	-11.12	-40.94
PB Ratio	2.12	0.91	3.02	2.13	4.47	13.70
P/FCF Ratio	-0.64	-0.64	-4.21	-5.52	-15.03	-57.32
P/OCF Ratio	-0.64	-0.64	-4.21	-5.52	-15.03	-57.32
EV/EBITDA Ratio	0.26	0.26	-1.65	-2.21	-8.46	-37.82
EV/EBIT Ratio	0.26	0.26	-1.65	-2.21	-8.46	-37.82
EV/FCF Ratio	0.28	0.28	-2.40	-2.75	-11.44	-52.95
Debt / Equity Ratio	-	-	0.00	-	-	-
Debt / EBITDA Ratio	-	-	0.00	-	-	-
Debt / FCF Ratio	-	-	0.00	-	-	-
Quick Ratio	4.13	4.13	4.19	12.85	14.22	18.25
Current Ratio	4.17	4.17	4.21	12.98	14.28	18.27
Return on Equity (ROE)	-116.00%	-116.00%	-77.80%	-41.10%	-43.70%	-60.00%
Return on Assets (ROA)	-88.20%	-88.20%	-67.30%	-39.00%	-41.60%	-55.60%
Return on Capital (ROIC)	-158.05%	-158.05%	-104.35%	-48.19%	-41.48%	-34.24%
Earnings Yield	-71.00%	-166.13%	-34.51%	-22.52%	-9.00%	-2.44%
FCF Yield	-66.40%	-155.38%	-23.73%	-18.11%	-6.65%	-1.74%
Buyback Yield / Dilution	-8.69%	-8.69%	-1.98%	-13.81%	-17.56%	-0.32%
Total Shareholder Return	-8.69%	-8.69%	-1.98%	-13.81%	-17.56%	-0.32%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).